Use of schisandrin B in anti-liver fibrosis

A technique for schisandra B and liver fibrosis, which is applied in the fields of inhibiting the proliferation of hepatic stellate cells or inhibiting the DNA synthesis of hepatic stellate cells, and in the field of inhibiting the proliferation of hepatic stellate cells or inhibiting the DNA synthesis of hepatic stellate cells. Compound recipes have many problems, such as unsatisfactory effects, complex ingredients, etc., to achieve strong drug efficacy, good application prospects, and the effect of improving the degree of liver fibrosis or cirrhosis

Inactive Publication Date: 2014-06-18
INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, it has been reported in the literature that traditional Chinese medicine compound can improve the occurrence of liver fibrosis and cirrhosis, but the compound has many medicinal flavors, generally more than 3 flavors, complex ingredients and unsatisfactory effect
At present, there are also literature reports on the use of traditional Chinese medicine monomers such as ursolic acid and silymarin in the treatment of liver fibrosis, but the effects are not satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of schisandrin B in anti-liver fibrosis
  • Use of schisandrin B in anti-liver fibrosis
  • Use of schisandrin B in anti-liver fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1: Establishment of primary rat hepatic stellate cell proliferation model

[0052] 1. Reagents and Cells

[0053] Male Wistar rats, about 400 g, were provided by the Experimental Animal Center of the Academy of Military Medical Sciences.

[0054] 96-well plate, Corning; Type Ⅳ collagenase, sigma company; Pronase E, Roche company; DNase Ⅰ, Roche company; DMEM medium, Beijing Tianrun Shanda Biotechnology Co., Ltd.; Heparin sodium, Sinopharm Chemical Reagent Co., Ltd. ; PDGF-BB, Peprotech Corporation.

[0055] Peristaltic pump, Baoding Lange Constant Flow Pump Co., Ltd.; multi-head cell sample collector, Zhejiang Shaoxing ZT-2 type; liquid scintillation counter, PerkinElmer Company, model: 1450-024.

[0056] 2. Experimental method

[0057] use 3 The effect of different concentrations of PDGF-BB on HSC DNA synthesis was observed by H-TdR incorporation method. The method is to obtain primary rat HSCs by in situ perfusion method (Jiang Tao, Liang Liwu, Guo Shun...

Embodiment 2

[0060] Embodiment 2: Schizandrin B on the synthesis of HSC proliferation model DNA of primary culture influences

[0061] 1. Reagents and Cells

[0062] Schizandrin B can be purchased commercially (purchased from Shanghai Tongtian Biotechnology Co., Ltd., product number E-0133, with a purity greater than 97%) or prepared by referring to the method in Example 7. In the following examples, Schizandrin B is commercially available.

[0063] 2. Experimental method

[0064] use 3 The H-TdR incorporation method was used to observe the effect of Schisandrin B on the DNA synthesis of the primary HSC proliferation model. The method is to obtain primary rat hepatic stellate cells by in situ perfusion method, and press 1×10 5 Cells / ml were inoculated in 96-well plates, and after culturing for 72 hours, PDGF-BB25ng / ml was used to cause the proliferation model of hepatic stellate cells, and Schizandrin B was added at the same time, so that the concentrations after adding to the reac...

Embodiment 3

[0067] Example 3: Toxic effect of Schisandrin B on primary cultured HSC

[0068] 1. Experimental materials

[0069] Thiazolyl Blue Tetrazolium Bromide (MTT), Amreaco Company; Ensipire multifunctional microplate reader, PerkinElmer, model: 2300; other reagent sources are the same as in Example 1.

[0070] 2. Experimental method

[0071] The toxic effect of schisandrin B on primary HSC was observed by MTT method. The method is to obtain primary rat hepatic stellate cells by in situ perfusion method, and press 1×10 5 cells / ml density inoculated in 96-well plates, after culturing for 72 hours, PDGF-BB 25ng / ml was used to cause the proliferation model of hepatic stellate cells, and Schizandrin B was added at the same time, so that the concentrations after adding to the reaction system were 3, 10, 30 μM, cultured for 20 hours, added 20 μl of 0.25% MTT to each well, continued to cultivate for 4 hours, added 150 μl of 10% SDS and cultivated overnight, and detected its absorbance ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of traditional Chinese medicines or the pharmaceutical chemistry, and relates to a use of schisandrin B or a Chinese magnoliavine extract in the preparation of medicines for treating and / or adjunctively treating and / or preventing liver fibrosis or liver cirrhosis, medicines for treating or adjunctively treating diseases caused by the liver fibrosis or liver cirrhosis, or medicines for inhibiting liver stellate cell proliferation or DNA synthesis. The invention also relates to a method for inhibiting the liver stellate cell proliferation or inhibiting the liver stellate cell DNA synthesis in vitro / in vivo, and a medicinal composition containing the schisandrin B or the Chinese magnoliavine extract. It is proved that the schisandrin B can obviously improve the liver fibrosis or the liver cirrhosis degree, has no obvious hepatotoxicity and has a good application prospect.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine or medicinal chemistry, and relates to the use of a Chinese medicine monomer for anti-hepatic fibrosis, in particular, it relates to the use of a Chinese medicine monomer Schisandra B in the preparation of treatment and / or adjuvant treatment and / or prevention of liver fibrosis and Use in drugs for liver cirrhosis, or drugs for inhibiting proliferation of hepatic stellate cells, or for inhibiting DNA synthesis of hepatic stellate cells. The present invention also relates to a pharmaceutical composition containing schisandrin. The present invention also relates to a method for inhibiting proliferation of hepatic stellate cells or inhibiting DNA synthesis of hepatic stellate cells in vitro / in vivo. Background technique [0002] Hepatic fibrosis is a pathological change in which excessive deposition of extracellular matrix in the liver leads to abnormal liver structure or (and) function. I...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/36A61K36/57A61P1/16
Inventor 张永祥迟莉周文霞肖智勇
Owner INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap